Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

NCT02796261 is registered in ClinicalTrials.gov with Orbus Therapeutics, Inc. as lead sponsor.

NCT NCT02796261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02796261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Lead sponsor
Orbus Therapeutics, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2016
Completion date
June 30, 2023
Enrollment
343 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, recurrent anaplastic astrocytoma